Previous 10 | Next 10 |
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million...
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The company announced that it will release its 2023 financial results after market close on Feb....
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on February ...
Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocar...
A recent study has revealed that Ramadan fasting may be associated with a lower risk of developing chronic diseases. Published in the “ American Journal of Clinical Nutrition ,” the study found that Ramadan fasting was linked with a significant reduction in the risk of breast, col...
A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023 The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplan...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of All...
Humans need a healthy amount of muscle mass to stay spry and healthy, especially as they age. High muscle mass helps to increase metabolism and makes it easier to maintain a healthy weight level, says Washington, D.C., dietician Caroline Thomason, RD, CDCES. She explains that muscles are among ...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market ...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today ann...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...